



pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015

Watertown, MA (June 24, 2015) – pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton, president and CEO of pSivida Corp., will present at the International Symposium on Ocular Pharmacology and Therapeutics Clinical meeting in Berlin, Germany July 9-12, 2015. This meeting will focus on the significant revolution that has and continues to take place with new drugs and modes of delivery to treat eye disease. Dr. Ashton's presentation is part of the "Innovation in Ophthalmology" section to be held on Saturday, July 11.

pSivida's patented Durasert™ technology, which can deliver drug for a predetermined period ranging from months to years, is the basis of three of only four sustained release products approved by the FDA to treat back of the eye diseases. The most recent is ILUVIEN® for diabetic macular edema, and Medidur™ for posterior uveitis is in Phase III clinical trials. These products, which use the same injectable micro-insert, provide sustained delivery of a corticosteroid to the back of the eye for three years from a single injection.

"Back of the eye disease present significant challenges to traditional delivery methods," Dr. Ashton said. "Eye drops have difficulty reaching the back of the eye; systemically administered drugs can cause significant side effects when delivered in sufficient quantity to reach the back of the eye; and injections of drugs directly to the back of the eye typically have transient therapeutic effect, requiring frequent injections. Our technology can provide extended delivery over months or years at a controlled, sustained release rate directly to the target site. "

This meeting marks the 12th gathering of the ISOPT *Clinical*, offering a relevant and updated scientific program that provides for direct interactions of its delegates, who are physicians and researchers from throughout the world.

About pSivida Corp.

pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, is licensed to Alimera Sciences and sold in the U.S. and four EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Medidur™, a micro-insert for posterior uveitis, is currently in pivotal phase III clinical trials with an NDA anticipated in the first half of 2017. pSivida's preclinical development program is focused on using its core

platform technologies, Durasert™ and/or Tethadur™, to deliver drugs and biologics to treat wet and dry age-related macular degeneration (AMD), glaucoma, osteoarthritis and other diseases.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statement. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: actual final IOP safety results for Medidur Phase III trials; ability to achieve profitable operations and access to capital; fluctuations in operating results; further impairment of intangible assets; decline in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; number and cost of clinical trials and data necessary to support an NDA for, approval by Indian regulators of the trial design for, timing of filing the NDA for, and regulatory approval and successful commercialization of, Medidur; delays in completion of clinical trials; increases in cost of clinical trials; changes in, or misunderstandings with respect to, FDA guidance on required clinical trials; development of the Latanoprost Product and any exercise by Pfizer of its option; ability of Tethadur to successfully deliver large biologic molecules and to develop products using it; ability to successfully develop product candidates, complete clinical trials and receive regulatory approvals; ability to market and sell products; success of current and future license agreements; termination of license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements together with these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Follow pSivida on social media:

Twitter: <https://twitter.com/pSividaCorp>

Facebook: <https://www.facebook.com/pages/PSivida-Corp/544893792199562>

LinkedIn: <http://www.linkedin.com/company/psivida>

Google+: <https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts>

The President's Blog: <http://www.thechairmansblog.com/paul-ashton>

For more information on pSivida, visit www.psivida.com.

Contact in US:

Beverly Jedynak
President
Martin E. Janis & Company, Inc.
T: 312-943-1123
M: 773-350-5793
bjedynak@janispr.com

Contact in Australia:

Rudi Michelson
Monsoon Communications
T: 03 9620 3333
M: 0411 402 737
rudi@monsoon.com.au